CANY
GHDX

Caxton Associates (New York)’s Genomic Health, Inc. GHDX Stock Holding History

Caxton Associates (New York)’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-4,323
Closed -$303K – 579
2019
Q1 		$303K Buy
+4,323
New +$321K 0.04% 247

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Caxton Associates (New York)'s GHDX Position: Q2 2019 in Review

Caxton Associates (New York) sold out of Genomic Health, Inc. (GHDX) in Q2 2019, closing a stake of 4,323 shares — an estimated $303K sold.

Caxton Associates (New York) first reported a position in GHDX in Q1 2019 and held it in 1 quarter. The position peaked at $303K in Q1 2019. 215 funds tracked by Wall St. Rank hold GHDX as of Q2 2019.

  • Caxton Associates (New York) reported no remaining Genomic Health, Inc. position as of Q2 2019 after selling out during the quarter.
  • Caxton Associates (New York) sold 4,323 Genomic Health, Inc. shares in Q2 2019, an estimated $303K.
  • Caxton Associates (New York) first reported a position in Genomic Health, Inc. in Q1 2019 and held it in 1 quarter.
  • Caxton Associates (New York)'s Genomic Health, Inc. position peaked at $303K in Q1 2019.
  • 215 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q2 2019.

Based on Caxton Associates (New York)'s 13F filing for Q2 2019, filed 14 Aug 2019.